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Despite being among the ten most common cancers with high recurrence rates
worldwide, there have been no major breakthroughs in the standard treatment options
for bladder cancer in recent years. The use of a human amniotic membrane (hAM)
to treat cancer is one of the promising ideas that have emerged in recent years. This
study aimed to investigate the anticancer activity of hAM homogenate on 2D and 3D
cancer models. We evaluated the effects of hAM homogenates on the human muscle
invasive bladder cancer urothelial (T24) cells, papillary cancer urothelial (RT4) cells
and normal porcine urothelial (NPU) cells as well as on human mammary gland non-
tumorigenic (MCF10a) cells and low-metastatic breast cancer (MCF7) cells. After 24 h,
we observed a gradual detachment of cancerous cells from the culture surface, while
the hAM homogenate did not affect the normal cells. The most pronounced effect hAM
homogenate had on bladder cancer cells; however, the potency of their detachment
was dependent on the treatment protocol and the preparation of hAM homogenate.
We demonstrated that hAM homogenate significantly decreased the adhesion, growth,
and proliferation of human bladder invasive and papillary cancer urothelial cells and did
not affect normal urothelial cells even in 7-day treatment. By using light and electron
microscopy we showed that hAM homogenate disrupted the architecture of 2D and 3D
bladder cancer models. The information provided by our study highlights the detrimental
effect of hAM homogenate on bladder cancer cells and strengthens the idea of the
potential clinical application of hAM for bladder cancer treatment.
Keywords: cancer, urothelium, 2D and 3D in vitro models, light and electron microscopy, proliferation, cell cycle
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INTRODUCTION
The incidence of bladder cancer is steadily increasing, especially
in industrialized countries (Bray et al., 2018). The disease is more
prevalent in men, who accounted for 440,864 out of 573,278 new
cases diagnosed in 2020 (Sung et al., 2021). The predominant
histologic type of bladder cancer is urothelial carcinoma and out
of all newly diagnosed cases, approximately 75% are non-muscle
invasive bladder cancer (NMIBC) and 25% are muscle-invasive
bladder cancer (MIBC) (Sanli et al., 2017; Patel et al., 2020).
The main challenge of NMIBC management is its high
recurrence rate. Namely, approximately 50–70% of NMIBC cases
will recur and 15–20% will progress to MIBC (Sylvester et al.,
2006; Isharwal and Konety, 2015; Knowles and Hurst, 2015; Patel
et al., 2020). Due to the high recurrence rate and consequent
disease monitoring requirements, bladder cancer has one of
the highest lifetime treatment costs per patient among cancers
(Sievert et al., 2009). The prognosis for patients with NMIBC
is very encouraging as the 5-year survival rate is approximately
90%, however, the 5-year survival rate of patients with the
metastatic disease is still merely 6% (Funt and Rosenberg, 2017).
While research of tumor biology resulted in major therapeutic
advances in several other cancers, systemic therapy for bladder
cancer is developing more slowly. In the field of intravesical
therapy for NMIBC there have not been any major changes,
despite global shortage of Bacillus Calmette-Guerin (BCG)
immunotherapy, which is the gold standard for treatment of
intermediate and high risk NMIBC (Pettenati and Ingersoll,
2018; Patel et al., 2020). Moreover, despite the increased use of
neoadjuvant and adjuvant systemic chemotherapy for MIBC, the
long-term survival rates remain unchanged (Advanced Bladder
Cancer (ABC) Meta-analysis Collaboration, 2005a,b; Zehnder
et al., 2013; Hermans et al., 2016). Nevertheless, it is encouraging
that the initial results of systemic immunotherapy in regard
to the disease progression and survival are promising (Powles
et al., 2014, 2017; Rosenberg et al., 2016; Apolo et al., 2017;
Balar et al., 2017; Bellmunt et al., 2017; Farina et al., 2017;
Sharma et al., 2017; Vaughn et al., 2018; Fradet et al., 2019).
Overall, there is a great need for the development of novel
therapeutic approaches that would improve survival and decrease
the recurrence, particularly for NMIBC.
The human amniotic membrane (hAM) is a placenta-derived
biomaterial that has a long history of use in regenerative medicine
(Malhotra and Jain, 2014; Silini et al., 2015; Shakouri-Motlagh
et al., 2017). It is composed of a monolayer of human amniotic
epithelial cells (hAEC), basal lamina, and hAM stroma, which is
further divided into a compact layer, a layer of human amniotic
mesenchymal stromal cells (hAMSC) and a spongy layer (Parolini
et al., 2008; Lee et al., 2016). Besides having properties that are
beneficial for use in tissue engineering and regenerative medicine,
such as promotion of epithelization (Koizumi et al., 2000; Gicquel
et al., 2009; Insausti et al., 2010; Jin et al., 2015), decrease of
scarring (Rowe et al., 1997; Tseng et al., 1999; Koh et al., 2007;
Santanna et al., 2016), low immunogenicity (Kubo et al., 2001;
Szekeres-Bartho, 2002; Hortensius et al., 2016; Magatti et al.,
2018), antimicrobial (Tehrani et al., 2013; Mao et al., 2017, 2018;
Yadav et al., 2017; Ramuta et al., 2020b), anti- and pro-angiogenic
properties (Hao et al., 2000; Niknejad et al., 2013), recent studies
demonstrated that hAM also possesses anticancer properties
(Magatti et al., 2012; Mamede et al., 2014, 2015, 2016; Niknejad
et al., 2014, 2016; Bu et al., 2017; Riedel et al., 2019; Ramuta
et al., 2020a). Moreover, recently we showed that hAM scaffolds
hinder the growth and invasive potential of MIBC cells (Ramuta
et al., 2020a). However, when considering the application of hAM
scaffolds in urology, their handling might be rather difficult.
Hence, to facilitate the translation of hAM from bench to
bedside, the development of novel hAM-derived preparations
(e.g., hAM homogenate) that would allow a more straightforward
administration is crucial. Therefore, the aim of our study was to
investigate the anticancer activity of hAM homogenates on 2D
and 3D in vitro models of NMIBC and MIBC.
MATERIALS AND METHODS
Cell Cultures
Human bladder invasive cancer urothelial (T24) cells, papillary
cancer urothelial (RT4) cells and low-metastatic breast cancer
(MCF7) cells were purchased from ATCC (Manassas, VA,
United States), seeded at a seeding density of 5 × 104 cells/cm2
and cultured in a 1:1 mixture of A-DMEM medium (Gibco,
Thermo Fisher Scientific, Waltham, MA, United States)
and F12 (Sigma-Aldrich, St. Louis, MO, United States),
supplemented with 5% fetal bovine serum (FBS) (Invitrogen,
Carlsbad, CA, United States), 4 mM GlutaMAX (Gibco,
Thermo Fisher Scientific, Waltham, MA, United States),
100 µg/ml streptomycin, and 100 U/ml penicillin (Thermo
Fisher Scientific, United States). Human mammary gland
non-tumorigenic (MCF10a) cells were obtained from ATCC
(Manassas, VA, United States), seeded at a seeding density of
5 × 104 cells/cm2 and cultured in MEBMTM Basal Medium
(CC-3151, Lonza, Basel, Switzerland) supplemented with
MEGMTM SingleQuotsTM Supplement Pack (CC-4136, Lonza,
Basel, Switzerland) and 5% horse serum (HS) (Gibco, Thermo
Fisher Scientific, Waltham, MA, United States).
The use of porcine urinary bladders for preparation of primary
urothelial cells was approved by the Veterinary Administration
of the Slovenian Ministry of Agriculture and Forestry in
compliance with the Animal Health Protection Act and the
Instructions for Granting Permits for Animal Experimentation
for Scientific Purposes. Normal porcine urothelial (NPU) cells
were established as previously described (Kreft et al., 2005;
Visnjar et al., 2012; Visnjar and Kreft, 2015). The NPU
cells were seeded at a seeding density of 1 × 105 cells/cm2
and maintained in a 1:1 mixture of MCDB153 medium
(Sigma-Aldrich, St. Louis, MO, United States) and Advanced
Dulbecco’s modified essential medium (Invitrogen, Carlsbad,
CA, United States), supplemented with (final concentrations are
shown) 0.1 mM phosphoethanolamine (Sigma-Aldrich, St. Louis,
MO, United States), 15 µg/ml adenine (Sigma-Aldrich, St. Louis,
MO, United States), 0.5 µg/ml hydrocortisone (Sigma-Aldrich,
St. Louis, MO, United States), 5 µg/ml insulin (Sigma-Aldrich,
St. Louis, MO, United States), 2 mM GlutaMAX (Gibco, Thermo
Fisher Scientific, Waltham, MA, United States), 100 µg/ml
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streptomycin, 100 U/ml penicillin (Thermo Fisher Scientific,
United States) and 2.5% FBS. Upon reaching confluence, NPU
cells were cultured in the serum-free medium, supplemented
with a calcium concentration (CaCl2) of 2.5 mM for additional
3 weeks. All cell cultures were maintained at 37◦C in a humidified
atmosphere at 5% CO2.
All of the cell cultures were maintained in culture media
containing antibiotics, while the assays described in sections
“Cell detachment assay,” “Cell Attachment Assay,” “Analysis of
the Effect of hAM Homogenate on the Proliferation Rate of
Cancer Urothelial Cells,” “Western Blot Analysis,” “Scanning and
Transmission Electron Microscopy,” and “Analysis of the Effect
of hAM Homogenate on the 3D Architecture of Bladder Cancer
Urothelial Spheroids” were performed using the antibiotics-
free culture media.
Preparation of Human Amniotic
Membrane Homogenate
The studies involving human participants were reviewed and
approved by the National Medical Ethics Committee of the
Republic of Slovenia. The hAM homogenate was prepared
as previously described (Šket et al., 2019; Ramuta et al.,
2020b). Briefly, 32 hAMs were obtained at the time of elective
Cesarean sections from healthy volunteers (age 25–38 years
old) who previously signed a written informed consent form.
All volunteers were serologically negative for hepatitis B and
C, HIV, and syphilis. Right after delivery, hAM was separated
from the chorion, washed with sterile phosphate-buffered saline
(PBS), and cut into small pieces. The volume of hAM pieces was
measured, and the appropriate culture medium was immediately
added in the ratio of 1:4 (one part of hAM pieces and
three parts of appropriate culture medium without FBS, HS,
antibiotics or CaCl2). The mixture was homogenized with two
different homogenizers: Russell Hobbs 21350-56 (Failsworth,
United Kingdom, 300 W, only one speed up to 24000 rpm),
and/or Kinematica Polytron R© PT 3100 D (Kinematica, Luzern,
Switzerland, 1200 W, speed range 500–30 000 rpm) (Table 1).
Furthermore, homogenization with Kinematica Polytron R© PT
3100 D was performed at three different speeds: 20000, 10000,
and 5000 rpm. The prepared homogenates were filtered through
sterile nylon membrane filter with pore size <1 mm, stored
at−80◦C for up to 6 months and underwent only one freeze-thaw
TABLE 1 | Specifications of homogenizers used for studying anticancer properties
of hAM homogenate.


















cycle. Prior to each experiment, a sufficient volume of FBS
(final concentration of 5%; for cancer cell lines), HS (final
concentration of 5%; for MCF10a) or CaCl2 (final concentration
of 2.5 mM; for NPU cells) was added to the respective hAM
homogenates. The homogenate prepared with Russell Hobbs
was used in all the experiments and we refer to the so-
prepared homogenate as hAM homogenate or RH. In contrast,
we refer to the hAM homogenate prepared with Kinematica
Polytron R© PT 3100 D as PT1 (homogenization at 20000 rpm),
PT2 (homogenization at 10000 rpm) and PT3 (homogenization
at 5000 rpm). Processing of hAM was performed under sterile
conditions in a clean room and laminar flow cabinets of biosafety
level 2. All experiments using the hAM homogenate were
performed without antibiotics. The main steps of the preparation
of hAM homogenate are illustrated in Figure 1.
Cell Detachment Assay
To investigate the effect of hAM homogenate on the cell
detachment status, the T24, RT4, NPU, MCF7, and MCF10a
cells were cultured to confluency and incubated with hAM
homogenate for 24-h. Moreover, to further evaluate whether the
effect of hAM homogenate on the cell detachment depends on
the homogenate preparation (see the protocols in “Preparation
of Human Amniotic Membrane Homogenate”) and treatment
protocols, T24, RT4 and NPU cells were cultured to confluency
and then treated with different homogenate preparations (a)
every 24 h for three consecutive days or (b) 2 h per day for
three consecutive days. Additionally, we performed experiments
with the NPU cells, treated with hAM homogenate every 24-
h for a total of seven consecutive days and then cultured in
an appropriate culture medium without hAM homogenate for
three more weeks. After each treatment, the cells were rinsed
three times with culture medium, and 5–10 random bright-field
images per well were obtained using an inverted phase-contrast
microscope Eclipse E300 (Nikon, Tokyo, Japan). The area of
detached cells was analyzed with ImageJ software (Wright Cell
Imaging Facility, Toronto, ON, Canada) and presented as a
percentage of the total field view area (% of surface area covered).
Untreated cells were grown in an appropriate culture medium
without the hAM homogenate and served as negative controls.
The volume of hAM homogenate or an appropriate culture
medium without hAM homogenate was equivalent for all cell
types and treatment protocols.
Cell Attachment Assay
For the attachment assay, T24 and RT4 cells were seeded in a
24-well plate (5 × 104 cells/well) and cultured in the presence
or absence (controls) of hAM homogenate for three consecutive
days. Every 24 h, fresh hAM homogenate was added to the
wells. To quantify the number of attached cells, the hAM
homogenate or culture medium was removed. The cells were
fixed with 4% formaldehyde (w/v) and stained with Giemsa
(Merck, Kenilworth, NJ, United States). The attached cells were
imaged by stereo microscope SMZ800N (Nikon, Tokyo, Japan)
equipped with MikroCam PRO HDMI 5MP (Bresser Gmbh,
Rhede, Germany) and then scanned using the ScanMaker 8700
(Microtek, Hsinchu, Taiwan). The resulting images obtained by
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FIGURE 1 | Human amniotic membrane (hAM) homogenate preparation protocol. (A) Separation of the hAM from human chorionic membrane (hCM). (B) Washing
the hAM in sterile PBS. (C) Measuring the volume of hAM pieces. (D) Addition of an appropriate culture medium to the hAM pieces in the ratio of 1:4. (E) Filtration of
hAM homogenate through sterile nylon membrane filter with pore size <1 mm, after completed homogenization. (F) Cryopreserved hAM homogenate is used for
further experiments.
the stereomicroscope were converted to an 8-bit binary images
using the ImageJ software. The integrated density of the attached
cells was quantified and presented as a mean relative intensity
(arbitrary units).
Analysis of the Effect of hAM
Homogenate on the Proliferation Rate of
Cancer Urothelial Cells
Confluent cultures of T24 and RT4 cells were treated with
culture medium (controls) or hAM homogenate for three
consecutive days, and the proliferation rate was evaluated after
24, 48, and 72 h of treatment. The proliferation rate was
determined using the Click-it Plus EdU Alexa Fluor 488 Imaging
Kit (Thermo Fisher Scientific, Waltham, MA, United States)
and subsequent analysis was performed with ImageJ software.
Briefly, 24 h before the analysis, the T24 and RT4 cells
were incubated at 37◦C and 5% CO2 in the culture medium
(controls) supplemented with 10 µM 5-ethynyl-2′-deoxyuridine
(EdU) or hAM homogenate supplemented with EdU. Next,
the samples were fixed with 4% formaldehyde for 15 min
at room temperature (RT), washed three times in 3% bovine
serum albumin (BSA) (Thermo Fisher Scientific, Waltham, MA,
United States) in PBS and permeabilized by incubation in
0.5% Triton-X-100 (Thermo Fisher Scientific, Waltham, MA,
United States) in PBS for 20 min at RT. Afterward, the samples
were washed three times in 3% BSA in PBS and incubated for
30 min at RT in the Click-it Plus reaction buffer containing
Alexa Fluor picolyl azide according to the manufacturer’s
instructions. Next, the samples were washed three times with
3% BSA in PBS and the nuclei were stained using DAPI.
The samples were examined using the fluorescence microscope
AxioImager.Z1 equipped with ApoTome (Zeiss, Jena, Germany).
Furthermore, 5–10 images for each sample were taken and
the percentage of proliferating cells was determined with the
ImageJ software.
Western Blot Analysis
Confluent cultures of T24 and RT4 cells were treated with
culture medium (controls) or hAM homogenate for 24 h and
the expression of cyclin D1 was evaluated. After the treatment,
the T24 and RT4 cells were collected and lysed in ice-cold
RIPA buffer (Merck, Kenilworth, NJ, United States), containing
a cocktail of protease and phosphatase inhibitors (Thermo
Fisher Scientific, Waltham, MA, United States). Total protein
levels were quantified using the Pierce BCA Protein Assay
Kit (Thermo Fisher Scientific, Waltham, MA, United States).
Equivalent concentrations of protein (50 mg/lane) were separated
using 4–20% Novex WedgeWell Tris-Glycine Gels (Invitrogen,
Carlsbad, CA, United States) and then transferred onto
a nitrocellulose membrane (Sigma-Aldrich, St. Louis, MO,
United States). Then the membranes were blocked in 5% skim
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milk in 0.1% Tris Buffered saline/Tween 20 (TBS-T) for 2 h at RT
and incubated overnight at 4◦C with primary antibodies against
cyclin D1 (dilution 1:500, sc-753, Santa Cruz Biotechnology,
Inc., Dallas, TX, United States) and anti-α-tubulin (dilution
1:2000; T6199, Sigma-Aldrich, St. Louis, MO, United States).
The next day, the membranes were washed with TBS-T and
immediately incubated for 1 h at RT with secondary antibodies
conjugated with horseradish peroxidase (dilution 1:1000, A6154,
Sigma-Aldrich, St. Louis, MO, United States). Visualization
of the protein bands was performed using the SuperSignal
West Pico Chemiluminescent Substrate (Thermo Scientific,
Waltham, MA, United States). ImageJ software was used to carry
out the densitometric analysis. α-tubulin served as a loading
control. Western analyses shown here are representative of three
independent experiments.
Scanning and Transmission Electron
Microscopy
Confluent cultures of T24, RT4, and NPU cells were treated
with culture medium (controls) or hAM homogenate for 24
and 72 h, respectively. The samples were prepared for scanning
and transmission electron microscopy as described previously
(Visnjar et al., 2012; Jerman et al., 2014; Ramuta et al., 2020b).
Briefly, for scanning electron microscopy the samples were fixed
with 2% formaldehyde (w/v) and 2% glutaraldehyde (v/v) in
0.2 M cacodylate buffer (pH 7.4) for 3 h at 4◦C. Afterward, the
samples were rinsed overnight in the 0.2 M cacodylate buffer and
post-fixed in 1% (w/v) osmium tetroxide in 0.2 M cacodylate
buffer for 2 h at RT. Next, the samples were dehydrated in
a graded series of ethanol, followed by acetone. The samples
were then immersed in hexamethyldisilazane (Sigma-Aldrich, St.
Louis, MO, United States), air-dried overnight at RT, sputter-
coated with gold and examined at 25–30 kV with Vega 3
scanning electron microscope (Tescan, Brno, Czech Republic).
For transmission electron microscopy, the samples were fixed
with 3% formaldehyde (w/v) and 3% glutaraldehyde (v/v) in
0.1 M cacodylate buffer for 3 h at 4◦C. Next, the samples were
rinsed overnight in the 0.1 M cacodylate buffer and post-fixed
with 2% (w/v) osmium tetroxide for 1 h at RT. Afterward,
the samples were incubated in 2% uranyl acetate in H2O for
1 h at RT, followed by dehydration in graded series of ethanol
and embedding in Epon (Serva Electrophoresis, Heidelberg,
Germany). The semithin sections were prepared and stained
with toluidine blue and used to localize the position of ultrathin
sections and also to count the number of cell layers in in vitro
models. Then the ultrathin sections were prepared and contrasted
with uranyl acetate and lead citrate and examined at the operation
voltage 80 kV with the CM100 transmission electron microscope
(Philips, Eindhoven, The Netherlands) equipped with the CCD
camera (AMT, Danvers, MA, United States).
Analysis of the Effect of hAM
Homogenate on the 3D Architecture of
Bladder Cancer Urothelial Spheroids
To prepare the spheroids, the T24 and RT4 cells were seeded
in the appropriate culture medium on the ultra-low attachment
96-well plates (Corning, New York, NY, United States) at a
seeding density of 100,000 cells per well (T24 cells) or 50,000
cells per well (RT4 cells) and cultured at 37◦C and 5% CO2
for 96 h. Then the samples were incubated for additional 24
or 72 h in culture medium (controls) or hAM homogenate,
fixed in 4% formaldehyde for 60 min at 4◦C and then rinsed in
PBS for 30 min. Next, to prepare paraffin sections, the samples
were dehydrated through a graded series of ethanol into xylene
and embedded in paraffin wax and cut with microtome into
7 µm sections. Afterward, the paraffin sections were stained
with hematoxylin-eosin and examined with the Eclipse E200
microscope (Nikon, Tokyo, Japan).
Statistical Analyses
All the experiments were performed with at least 3 independent
biological samples of hAM. Within each experiment, three
technical replicates were carried out. Statistical analyses were
performed by GraphPad Prism 6 (GraphPad Software, La Jolla,
CA, United States) or SigmaPlot 12.0 (Systat Software, San
Jose, CA, United States) software. The quantified data are
presented as mean ± standard error of the mean (SEM).
When appropriate, the parametric unpaired two-tailed Student’s
t-test or the non-parametric Mann–Whitney test was used to
compare the statistical difference between two experimental
groups. Similarly, one-way analysis of variance (ANOVA) with
Tukey’s correction or Kruskal–Wallis with Dunn’s correction
for multiple comparisons was used to compare the statistical
difference between at least three experimental groups. A p-value
of <0.05 was considered statistically significant.
RESULTS
Effect of hAM Homogenate on
Detachment of Various Cancer Cell Lines
The confluent cultures of T24, RT4 NPU, MCF7, and MCF10a
were treated with an appropriate culture medium (controls)
and hAM homogenate for 24 h (Figures 2A–J). We found
that hAM homogenate caused the detachment of several cancer
cell lines. As shown in Figure 2, compared to control cells,
the surface area covered with muscle-invasive bladder T24
cells was significantly reduced to 22.7 ± 3.5% (Figures 2B,K).
The decrease in surface area coverage was, albeit to a lesser
extent, also detectable after 24-h hAM homogenate treatment
of non-invasive papillary urothelial RT4 cells (surface area
coverage 85.0 ± 3.7%; Figures 2D,K). On the other hand,
we did not observe detachment of normal urinary bladder
NPU cells (Figures 2F,K). Furthermore, 24-h incubation with
hAM homogenate caused detachment of the low-metastatic
breast cancer MCF7 cells (surface area coverage 92.5 ± 1.6%
(Figures 2H,K), but not of non-tumorigenic breast MCF10a
cells, which remained firmly attached to the well surface
(Figures 2J,K).
Most of the cancer cells detached from the culture surface,
which suggests that hAM homogenate may impair cell-cell
and cell-matrix interactions. Taken together, these results
demonstrate that cancer urothelial T24 and RT4 cells are more
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FIGURE 2 | Human amniotic membrane (hAM) homogenate causes
detachment of various cancer cell types but not of normal cells. (A,C,E,G,I)
After 24-h incubation with an appropriate culture medium without hAM
homogenate, T24, RT4, NPU, MCF7, and MCF10a cells remained firmly
attached to the culture surface. (B,D,H) 24-h incubation with hAM
homogenate resulted in significant detachment of cancer T24, RT4, and
MCF7 cells, (F,J) but not of normal NPU and MCF10a cells. The most
presentative images are shown. (K) The percentage of surface area covered
after 24-h treatment with hAM homogenate. The data are presented as mean
surface area coverage ± SEM (SEM, the standard error of the mean). Data
were obtained from three independent experiments, each performed with a
different biological sample of hAM. Within each experiment, three technical
replicates were performed. Scale bars: 100 µm. *p < 0.05.
sensitive to hAM homogenate treatment than the breast cancer
MCF7 cells. For this reason, biomimetic in vitro models of normal
and cancerous urothelium were a focus of our further analyses.
Effect of Different hAM Homogenates
and Treatment Protocols on the
Detachment of Cancer Urothelial Cells
To test whether different preparations of hAM homogenate
and treatment protocols have an effect on the amount of
cell detachment, we treated confluent T24 (Figures 3A1–E1),
RT4 (Figures 3A3–E3), and NPU cells (Figures 3A5–E5) with
four different types of hAM homogenates (PT1, PT2, PT3 and
RH) every 24 h for three consecutive days. Control cells were
incubated in culture medium only. Our results showed that
following the 24-h treatment with PT1, PT2, PT3, and RH, the
surface area covered with T24 was 52.6 ± 5.3%, 37.4 ± 4.8%,
26.2 ± 4.8%, and 22.7 ± 3.5%, respectively (Figure 3F). After
48-h treatment, we observed a similar decreasing trend in the
total surface area coverage of T24 cells. The surface area coverage
of T24 cells treated with PT1, PT2, PT3, and RH decreased
to 21.8 ± 5.1%, 9.0 ± 2.6%, 5.5 ± 2.2%, and 3.1 ± 1.3%,
respectively (Figure 3F). Noticeably, we observed the highest
effect of hAM homogenate-based cell detachment after 72-h
treatment. The surface area coverage of T24 cells treated with PT1
(Figures 3B2,F), PT2 (Figures 3C2,F), PT3 (Figures 3D2,F), and
RH (Figures 2E2,F) was 10.0 ± 4.4%, 2.7 ± 1.7%, 1.4 ± 0.8%,
and 0.5 ± 0.1%, respectively. Throughout the 72-h treatment
period, untreated control T24 cells remained firmly attached
to the culture surface (Figures 3A2,3F). What stands out in
Figure 3G is that only hAM homogenate prepared with RH had
any effect on the surface area coverage of RT4 cells. Our results
showed that after 24-, 48-, and 72-h treatment with RH, the
surface area covered with RT4 cells, decreased to 85.4 ± 3.7%,
85.5 ± 4.0%, and 77.5 ± 5.1%, respectively (Figures 3E4,G).
On the other hand, during the whole 72-h treatment period,
RT4 cells treated with PT1, PT2, and PT3 (Figures 3B4–D4,G)
remained attached to the culture surface like the control RT4
cells (Figures 3A4,G). In contrast to bladder cancer cells, our
study revealed that the normal bladder NPU cells remained
firmly attached to the culture surface after 24-, 48-, and 72-h
treatment with different hAM homogenate preparations or an
appropriate culture medium (Figures 3A6–E6,H). Furthermore,
we also showed that NPU cells remained attached following the 7-
day treatment of confluent NPU with hAM homogenate prepared
with RH or at any time during the following 21 days in the
appropriate culture medium. These results additionally confirm
that hAM homogenate does not affect detachment, morphology
and viability of NPU cells (Supplementary Figure 1).
We next aimed to determine whether 2-h treatment with
hAM homogenate would be sufficient to trigger cell detachment.
To do so, we treated confluent T24 (Figures 3I1–M1), RT4
(Figures 3I3–M3), and NPU cell cultures (Figures 3I5–M5)
with the same hAM homogenate preparations that we previously
mentioned, for 24 h/day for three consecutive days. Control
cells were incubated in a culture medium only. Our results
showed that RH caused detachment of T24 cells after 2 h on
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FIGURE 3 | Different hAM homogenate preparations cause detachment of cancer urothelial cells in a time-dependent manner. (A1–A6) Confluent cultures of T24,
RT4, and NPU cells incubated with an appropriate culture medium without hAM homogenate remained attached to the culture surface after the 72-h treatment
period. (B1–E2) 72-h treatment with different hAM homogenate preparations resulted in a significant detachment of T24 cells. (B3–E4) Only hAM homogenate
prepared with Russell Hobbs caused detachment of RT4 cells after the 72-h treatment period. (B5–E6) Different hAM homogenate preparations did not cause any
detachment of NPU cells after the 72-h treatment period. (I1–I6) Confluent cultures of T24, RT4, and NPU cells incubated with an appropriate culture medium
without hAM homogenate remained attached to the culture surface on the third day of the 2-h treatment period. (J1–M2) Different hAM homogenate preparations
caused detachment of T24 cells on the third day of the 2-h treatment period. (J3–M4) Confluent cultures of RT4 cells incubated with different hAM homogenate
preparations remained attached to the culture surface on the third day of the 2-h treatment period. (J5–M6) Different hAM homogenate preparations did not induce
detachment of NPU cells in three consecutive days of 2-h treatment. (F,N) The percentage of surface area covered with T24 cells after 24- and 2-h treatment for
three consecutive days. (G,O) The percentage of surface area covered with RT4 cells after 24- and 2-h treatment for three consecutive days. (H,P) The percentage
of surface area covered with NPU cells after 24- and 2-h treatment for three consecutive days. The quantified data here are presented as mean surface area
coverage ± SEM. Data were obtained from three independent experiments, each performed with a different biological sample of hAM. Within each experiment, three
technical replicates were performed. Scale bars: 100 µm. *p < 0.05.
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the first day of treatment (surface area coverage 93.4 ± 1.7%)
(Figure 3N). Furthermore, we observed a similar decreasing
trend after the second day of treatment with RH. The total surface
area covered with T24 cells decreased to 91.3± 2.0% (Figure 3N).
The most significant detachment of T24 cells was seen after
the third day of treatment (surface area coverage 73.2 ± 5.3%)
(Figure 3M2). hAM homogenates prepared with the Polytron
homogenizer caused detachment of T24 cells on the third day
of the 2-h treatment. Namely, the surface area coverage of T24
cells treated with PT1, PT2, and PT3, decreased to 75.4 ± 5.8%,
76.8 ± 5.2%, and 88.2 ± 4.2%, respectively (Figures 3J2–M2,N).
Untreated control T24 cells remained firmly attached to the
culture surface throughout the treatment period (Figures 3I2,N).
Furthermore, our study revealed that RT4 cells, treated with
PT1, PT2, PT3, and RH remained attached to the culture surface
in the same fashion as control RT4 cells, as the surface area
coverage did not drop below 97.8% at any time during the 2-h
treatment period (Figures 3I4–M4,O). Similarly, the percentage
of the surface area covered with NPU cells remained unaltered
after the consecutive 2-h treatment period with different hAM
homogenate preparations or an appropriate culture medium
(Figures 3I6–M6,P).
Taken together, we demonstrated that the potency of the hAM
homogenate varied between the preparations and the treatment
protocols used. We showed that hAM homogenate prepared
with Russell Hobbs has the greatest effect on the detachment
of urinary bladder cancer T24 and RT4 cells. Therefore, hAM
homogenate prepared with Russell Hobbs was used for the
remainder of the study.
Effect of hAM Homogenate on the
Attachment Capacity and the Growth
Dynamics of Cancer Urothelial Cells
Next, we aimed to evaluate the effect of hAM homogenate on
the cancer urothelial cell attachment capacity. For this reason,
we seeded and cultured T24 and RT4 cells in the presence
or absence of hAM homogenate for three consecutive days.
By measuring the staining intensity of the adherent cells, we
showed that hAM homogenate significantly reduced the ability
of T24 and RT4 cells to attach to the culture surface after
24-h incubation, in comparison with the untreated control
cells (Figures 4A–D,M,N). Furthermore, we also monitored
the cell growth for 48 and 72 h after the initial cell seeding
(Figures 4E–L,M,N). By comparing the slopes of the regression
lines, we observed that once the bladder cancer cells attached
to the culture surface, hAM homogenate hindered their growth
dynamics and inhibited their spreading potential. Moreover, this
inhibitory effect was present in both bladder cancer models,
but even more pronounced in the case of papillary urothelial
neoplasm RT4 cells.
Effect of hAM Homogenate on the
Proliferation Rate of Cancer Urothelial
Cells and Expression of Cyclin D1
Taking into account the results presented in the previous
section, we further investigated the impact of hAM homogenate
treatment for three consecutive days on the proliferation rate of
T24 and RT4 cells. hAM homogenate decreased proliferation of
T24 cells for 16.7% on day 1 (p < 0.05), for 21.1% on day 2
(p < 0.05), and for 3.0% on day 3 (p = 0.1535) of treatment
(Supplementary Table 1 and Figure 5A). Similarly, the hAM
homogenate also decreased the proliferation of RT4 cells, namely,
for 26.6% on day 1 (p < 0.05), for 17.6% on day 2 (p < 0.05),
and for 24.3% on day 3 (p < 0.05) (Supplementary Table 1
and Figure 5B). Furthermore, we performed a western blot
analysis, which showed a decrease in the expression level of cyclin
D1 in T24 cells after 24-h treatment with hAM homogenate
(Figures 5C,D). The western blot analysis of RT4 cells showed
a slight decrease in the expression levels of cyclin D1 after 24-
h treatment with hAM homogenate, but the difference was not
statistically significant (Figures 5C,D).
hAM Homogenate Adheres to the
Surface of Cancer Urothelial Cells and
Not of Normal Urothelial Cells
Using the scanning and transmission electron microscopy, we
first examined the ultrastructure of intact hAM, which is
comprised of a monolayer of hAEC, basal lamina and hAM
stroma (Figures 6A–G). Then we investigated the ultrastructure
of hAM homogenate, which is a mixture of hAM cells, mainly
hAEC and hAMSC, and hAM’s extracellular matrix (ECM).
As the hAM homogenate represents the majority of the hAM
(Figures 6A,C,C’,F,G), we detected large amounts of hAM’s ECM
also in hAM homogenates (Figures 6H–J’).
Then we investigated the effect of hAM homogenate on
the morphology, apical surface and ultrastructure of T24,
RT4, and NPU cells. Our results showed that T24 cells
incubated in a culture medium, have a mesenchymal morphology
characteristic of cancer cells, and there are large intercellular
spaces between the multiple layers of poorly connected cells
(Figures 7A–B’, 8A,B). The T24 cells incubated in hAM
homogenate retained the mesenchymal morphology and we
observed that the hAM homogenate covered a significant portion
of the cells (Figures 7C–D’). As the T24 cells were thoroughly
rinsed with culture medium prior to the fixation, this suggests
that the remaining hAM homogenate adhered strongly to
the surface of T24 cells (Figures 7C–D’). Furthermore, hAM
homogenate was found not only adhered to the apical surface of
the superficial layer of T24 cells, but also incorporated into the
large intercellular spaces of T24 cultures (Figures 8C,D).
The RT4 cells incubated in the culture medium were well
connected, without larger intercellular spaces, arranged
in multiple layers and exhibited epithelial morphology
(Figures 7E–F’, 8E,F). On the other hand, the RT4 cells
incubated in hAM homogenate retained their epithelial
morphology, but were covered with a significant amount of
hAM homogenate (Figures 7G–H’) that was strongly adhered
to their surface, despite the multiple rinses, which were
performed prior to the fixation of the cells. However, unlike
in the T24 cells, hAM homogenate was adhered only to the
superficial cell layers of RT4 cells and was not incorporated
between lower cell layers. For this reason, we then sought
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 8 June 2021 | Volume 9 | Article 690358
fbioe-09-690358 June 19, 2021 Time: 18:7 # 9
Janev et al. Anticancer Activity of Amniotic Membrane
FIGURE 4 | Human amniotic membrane (hAM) homogenate inhibits the cell attachment of T24 and RT4 cells and hinders their growth dynamics. (A,B) hAM
homogenate significantly reduced the ability of T24 cells to attach to the culture surface after 24-h incubation. (C,D) hAM homogenate significantly reduced the
ability of RT4 cells to attach to the culture surface after 24-h incubation. (E,F,I,J) hAM homogenate strongly inhibited the growth dynamics of the adhered T24 cells
48- and 72-h after the cell seeding. (G,H,K,L) hAM homogenate strongly inhibited the growth dynamics of the adhered RT4 cells 48- and 72-h after the cell seeding.
(M,N) Quantitative analysis of the relative intensity of adherent T24 and RT4 cells. The regression line of the untreated cells (black dashed line) has a steeper upward
tilt in comparison with the regression line of cells treated with hAM homogenate (red dashed line). The quantified data here is presented as a mean relative
intensity ± standard error of the mean (SEM). Data were obtained from three distinct experiments, each performed with a different biological sample of hAM. Within
each experiment, three technical replicates were carried. *p < 0.05.
to investigate whether hAM homogenate affected the total
number of cell layers. We quantified the maximum and the
minimum number of cell layers using the semithin sections
of treated and untreated RT4 samples after the 72-h treatment
period (Supplementary Figure 2). Our results showed that
the number of cell layers of RT4 cells decreased after the
72-h treatment with hAM homogenate (p = 0.071). Results
of the light microscopy (analysis of semithin sections) and
transmission electron microscopy indicate that treatment
of RT4 cells with hAM homogenate leads to desquamation
of the RT4 cells.
The apical plasma membrane of NPU was formed mainly
into ropy and rounded ridges, some of the NPU cells formed
also microridges, the ultrastructural characteristic of terminally
differentiated urothelial cells (Figures 7I–J’, 8I,J). The hAM
homogenate did not affect the morphology of the NPU cells and
in contrast to the effect on cancer cells, the hAM homogenate did
not adhere to the surface of NPU cells (Figures 7K–L’, 8K,L).
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FIGURE 5 | Human amniotic membrane (hAM) homogenate decreases proliferation of T24 and RT4 cells and downregulates the expression of cyclin D1 in T24 cells.
(A) The proliferation of T24 cells was decreased after 24, 48, and 72 h of treatment with hAM homogenate. (B) The proliferation of RT4 cells was decreased after 24,
48, and 72 h of treatment with hAM homogenate. (C,D) Western blot analysis of cyclin D1 and α-tubulin expression in T24 and RT4 cells treated with culture
medium (ctrl) or hAM homogenate. The western blot analysis showed significant decrease in the expression levels of cyclin D1 after 24-h treatment with hAM
homogenate in T24 cells. In RT4 cells, on the other hand, hAM homogenate induced slight but not significant decrease of cyclin D1 expression. All data shown here
were obtained from at least three independent replications of experiments using three biological samples of hAM; each experiment was performed in two technical
repeats for each condition. Bars represent mean ± SEM. *p < 0.05.
Effect of hAM Homogenate on the
Architecture of T24 and RT4 Spheroids
The T24 and RT4 spheroids, incubated in a culture medium,
retained a compact spherical structure (Figures 9A–B’,E–F’). On
the other hand, the incubation of T24 and RT4 spheroids in hAM
homogenate resulted in a disrupted 3D structure already after the
24 h of incubation and the effect was even more pronounced after
72 h of incubation. Namely, the treatment with hAM homogenate
led to larger intercellular spaces between cancer cells, which
occurred to a greater extent in the spheroids of T24 cells than RT4
cells. Furthermore, the hAM homogenate adhered to the surface
of T24 and RT4 and was also incorporated into the spheroids of
T24 and RT4 cells, which resulted in an even more disrupted 3D
structure (Figures 9C–D’,G–H’).
DISCUSSION
Different hAM Homogenate Preparations
Cause Detachment of Cancer Urothelial
Cells in a Time-Dependent Manner
In the present study, we showed that hAM homogenate induced
gradual detachment of cancerous cells from the surface, while
it did not affect the normal cells. Our results showed that
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FIGURE 6 | Structure of hAM and hAM homogenate. (A) Intact hAM is comprised of hAEC and hAM stroma, which is further divided into the compact layer, hAMSC
layer and spongy layer. (B,B’,D,E) hAEC are of cuboidal form, are well connected and exhibit numerous microvilli at the apical surface. (C,C’,F,G) The fibers that
form the extracellular matrix of hAM’s stroma are tightly interwoven. (D) The hAM stroma is further divided into the compact layer (CL), hAMSC layer (hAMSCL), and
spongy layer (SL). (H–J) The hAM homogenate applied to T24 cells. The hAM homogenate (white asterisks) consisted of the tightly interwoven fibers of the
extracellular matrix of hAM’s stroma and hAM-derived cells. The hAM homogenate applied to T24 cells adhered to the cell surface. The blue rectangles in panels
(B,C) mark the areas enlarged in panels (B’,C’). The green rectangle marks the area enlarged in panel (H’); the red rectangle marks the area enlarged in panel (H”).
White framed areas in panels (I,J) mark the areas enlarged in panels (I’,J’). (A) 100 µm, (B,C) 10 µm, (H) 50 µm, (H’) 25 µm, (D) 6 µm, (B’,C,E,H”,I,J) 2 µm, (J’)
600 nm, (F,G,I’) 400 nm.
the degree of detachment of cancer urothelial T24 and RT4
cells was greater than that of breast cancer MCF7 cells. On
the other hand, NPU cells remained attached to the culture
surface and without any observable changes in their morphology
even after a 7-day treatment with hAM homogenate. Taken
together, we conclude that the detachment of cancer cells was
hAM homogenate-specific. Furthermore, we observed that most
of cancer cell detachment came after the washing step, which
suggests that hAM homogenate may impair the cell-cell and/or
cell-matrix interactions. However, further studies are required to
determine the exact mechanism of action that leads to cancer
cell detachment.
Furthermore, we showed that the extent of cancerous
urothelial cell detachment differs between the treatment
protocols with hAM homogenate. We observed the highest
effect of hAM homogenate-based cell detachment after 24-h
treatment for three consecutive days. Moreover, we demonstrated
that 2-h treatment for three consecutive days is sufficient to
trigger detachment albeit to a lesser extent. In addition to
the treatment protocols, the potency of hAM homogenate
on the cancer urothelial cell detachment varied between the
used preparations. We observed that treatment with hAM
homogenate prepared with Russell Hobbs resulted in the highest
number of detached cancer cells. We hypothesize that the
differences in the effect might be attributed to the method
of homogenization. Namely, the Russell Hobbs homogenizer
uses the rotary blades to homogenize the tissue, whereas
Polytron uses dispersing aggregate that works based on the
rotor-stator principle to homogenize the tissue. The rotor-
stator homogenizers disrupt the tissue using the hydraulic and
mechanical shear and cavitation (Dhankhar, 2014). However,
they have a tendency to cause foaming, which might result
in low yield and denaturation of anticancer molecules that
are released from the homogenized tissue (Vitzthum, 2010;
Dhankhar, 2014). Another factor that might influence the
preservation of the anticancer molecules is the motor input
power of the homogenizers. Russell Hobbs homogenizer has a
300-Watt motor, whereas Polytron R© PT 3100 D has a powerful
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FIGURE 7 | The hAM homogenate adheres to the surface of T24 and RT4 cells. (A–B’) The T24 cells incubated in culture medium for 24 or 72 h had mesenchymal
morphology and there were large intercellular spaces between the cells. (C–D’) The 24- and 72-h incubation in hAM homogenate did not significantly affect the
morphology of T24 cells. The hAM homogenate adhered to the surface of T24 cells and a large portion of cells were covered with it. (E–F’) The RT4 cells incubated
in culture medium for 24 or 72 h had epithelial morphology and were well connected. (G–H’) The 24- and 72-h incubation in hAM homogenate did not significantly
affect the morphology of RT4 cells. The hAM homogenate adhered to the surface of RT4 cells and a large portion of cells were covered with it. (I–J’) The NPU cells
incubated in culture medium for 24 or 72 h retained the apical topography of well-differentiated normal urothelial cells. The apical plasma membrane appeared as
ropy and rounded ridges, and rarely microridges. (K–L’) The 24- and 72-h incubation in hAM homogenate did not significantly affect the morphology of NPU cells
and the hAM homogenate did not adhere to the surface of NPU cells. All data shown here were obtained from at least three independent replications of experiments
using three biological samples of hAM; each experiment was performed in 1–2 technical repeats for each condition. Red arrows–hAM homogenate. Frames in
panels (A–L) mark enlarged areas shown in panels (A’–L’). Scale bars: (A–L) 10 µm, (A’–L’) 5 µm.
1200-Watt motor. On the basis of our results, we hypothesize
that homogenization of hAM with low power rotary-blades
preserves the anticancer activity of hAM homogenate. Further
studies should determine the impact of homogenizing on
the anticancer molecules’ preservation and maintenance
of their function.
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FIGURE 8 | The hAM homogenate adheres to the surface of T24 and RT4 cells, but not the NPU cells, and incorporates between T24 cells. (A,B) The T24 cells
incubated in culture medium for 24 or 72 h had mesenchymal morphology and there were large intercellular spaces between the cells. (C,D) The hAM homogenate
(red asterisks) adhered to the surface of T24 cells and incorporated into the intercellular spaces. (E,F) The RT4 cells incubated in culture medium for 24 or 72 h had
epithelial morphology and were well connected. (G,H) Incubation in hAM homogenate for 24 or 72 h had no significant effect on RT4 cell morphology. The hAM
homogenate (red asterisks) adhered to the surface of RT4 cells. Some RT4 cells begin to desquamate. (I,J) The NPU cultures incubated in culture medium 24 or
72 h retained the typical ultrastructure of well-differentiated normal urothelial cells. (K,L) Incubation in hAM homogenate for 24 or 72 h had no significant effect on
NPU cell morphology, and the hAM homogenate did not adhere to the surface of NPU cells. All data shown here were obtained from at least three independent
replications of experiments using three biological samples of hAM; each experiment was performed in 1–2 technical repeats for each condition. Scale bars: (A,B)
1 µm, (C) 2 µm, (D) 4 µm, (E,F) 10 µm, (G) 8 µm, (H) 6 µm, (I,L) 600 nm.
hAM Homogenate Decreases the
Adhesion of Cancer Urothelial Cells and
Impedes Their Growth Dynamics
Cancer cell adhesion is a process, which plays a major role
during the metastasis of primary tumor cells (Bendas and Borsig,
2012). We showed that when incubated with hAM homogenate,
the ability of a suspension of T24 cells and RT4 cells to
attach to the culture surface was compromised. We postulate
that hAM homogenate may coat the surface of the cells and
consequently prevent the binding of the cancer cell to the
substratum. Furthermore, it is also possible that when seeded
with hAM homogenate, the majority of T24 and RT4 cells bind
to the components of the hAM ECM and hence are not able
to attach to culture surface. We, therefore, assume that reduced
cancer cell adhesion to culture surface after treatment with hAM
homogenate stem from the fact that hAM has already been
proven to be an excellent scaffold (Niknejad et al., 2008; Jerman
et al., 2014). In addition, our research group has already shown
that when seeded on hAM scaffolds, muscle-invasive bladder
T24 cells lose their invasive potential, which further supports
the argument that hAM may impede cancer progression and
metastasis (Ramuta et al., 2020a).
Even though hAM homogenate significantly inhibited the
adhesion, a small number of bladder cancer cells were still able to
attach to the culture surface. Nevertheless, we demonstrated that
hAM homogenate significantly slowed down the proliferation
rate of the cells that did attach. This inhibitory effect was even
more noticeable on the RT4 cells, which underlines the potential
of hAM homogenate for battling the highly recurrent papillary
NMIBC and flat (carcinoma in situ–CIS) bladder tumors.
hAM Homogenate Decreases the
Proliferation of Cancer Urothelial Cells
One of the key characteristics of cancer cells is their ability
to proliferate uncontrollably. Our results show that hAM
homogenate severely diminishes the proliferation rate of T24
and RT4 cells. This result is also in line with our previous
study, in which we demonstrated that hAM scaffolds diminish
the proliferation of T24 cells (Ramuta et al., 2020a). Next, we
investigated the effect of hAM homogenate on the expression
of cyclin D1, which is essential for G1/S phase transition and
its overexpression had been recorded in a large proportion
of human cancers, including bladder cancer (Tut et al., 2001;
Musgrove et al., 2011; Choi et al., 2012; Kopparapu et al., 2013).
Interestingly, we demonstrated that even though the basal level
of cyclin D1 was significantly higher in the RT4 cells, hAM
homogenate significantly downregulated the expression of cyclin
D1 only in the T24 cells. However, in RT4 cells, hAM homogenate
induced slight but not significant decrease of cyclin D1 expression
(Figure 5). Hence, we hypothesize that hAM homogenate affects
various cell cycle proteins, and that effect depends on the type of
cancer cell, which is supported by several studies showing that
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FIGURE 9 | Human amniotic membrane (hAM) homogenate disrupts the architecture of T24 and RT4 spheroids. (A–B’) The T24 spheroids incubated in culture
medium retained a compact spherical structure. (C–D’) 24- and 72-h incubations in hAM homogenate resulted in the disrupted 3D structure of T24 spheroids. hAM
homogenate adhered to the surface of T24 spheroids and was in some parts even incorporated into the spheroid. (E–F’) The RT4 spheroids incubated in culture
medium retained a compact spherical structure. (G–H’) 24- and 72-h incubations in hAM homogenate resulted in the disrupted 3D structure of RT4 spheroids as the
hAM homogenate adhered to the surface of RT4 spheroids and was in some parts incorporated into the spheroid. All data shown here were obtained from at least
three independent replications of experiments using three biological samples of hAM; each experiment was performed in at least three technical repeats for each
condition. Arrows–hAM homogenate. Scale bars: (A–D,E–H) 100 µm, (A’–D’,E’–H’) 20 µm.
hAM affects a plethora of cell cycle-related proteins in cancer
cells. Namely, it has been shown on human cancer cell lines of
hematopoietic origin (KG1, KG1a, Jurkat and U937 cell lines)
and non-hematopoietic origin (Girardi, HeLa, and Saos cell lines)
(Magatti et al., 2012) and on human ovarian cancer cell line
SK-OV-3 (Bu et al., 2017) that hAM-derived cells induce cell
cycle arrest in cancer cells in the G0/G1 phase (Magatti et al.,
2012; Bu et al., 2017). Magatti et al. (2012) demonstrated that
hAM-derived cells downregulate the expression of cyclins D2,
E1, and H and cyclin-dependent kinases (CDK4, CDK6, and
CDK2) and upregulate the negative regulators of cell cycle, such
as p15 and p21 (Magatti et al., 2012). Furthermore, Riedel et al.
(2019) showed that the conditioned medium of hAM induces
cell cycle arrest in the HepG2 human liver cancer cell line in
the G2/M phase (Riedel et al., 2019), which further supports
our hypothesis that hAM homogenate affects multiple targets
in the cell cycle of cancer cells. To conclude, we show for
the first time that the hAM homogenate decreases proliferation
and is also capable of altering the expression of cyclin D1 in
cancer urothelial cells. Importantly, we demonstrate that the
hAM homogenate affects the expression of cyclin D1 in cancer
urothelial cells, as the expression is significantly diminished in
the invasive cancer urothelial (T24) cells. On the other hand, the
expression of cyclin D1 in the papillary cancer urothelial (RT4)
cells treated with hAM homogenate is lower than in untreated
cell although, the difference is not statistically significant. Overall,
that indicates that different cell signaling pathways might be
affected by the hAM homogenate in various cells and further
research is needed to elucidate the complex and multimodal
activity of hAM homogenate in cancer cells of diverse origins.
The Extracellular Matrix of hAM
Homogenate Firmly Adheres to Bladder
Cancer Cells and Disrupts the 3D
Structure of Bladder Cancer Spheroids
We have demonstrated that hAM homogenate firmly adheres to
bladder cancer cells but not normal urothelium. We attribute this
to differences in chemical structure of plasma membranes and
membrane fluidity between cancer and normal cells as we have
shown previously (Yu et al., 2016; Zalba and Ten Hagen, 2017).
Moreover, our research group demonstrated that the amounts of
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cholesterol and sphingomyelin/cholesterol membrane domains
are highly increased in urothelial cancer cells in comparison
to normal urothelial cells (Resnik et al., 2015). There are also
many variations in the presence of various receptors, for example
integrins, which mediate contacts between the ECM and stromal
cells or tumor cells and are overexpressed in bladder cancer cells
(Grossman et al., 2000; Vallo et al., 2017; Arun et al., 2018; Liu
et al., 2020). Therefore, further studies are required to elucidate
the mechanism of adherence of hAM homogenate to cancer cells.
Improved targeting is one of the goals when developing
novel therapeutic approaches since many of the current
chemotherapeutics target all rapidly proliferating cells, which
leads to a high level of toxicity of the treatment and severe side
effects (Feitelson et al., 2015). Therefore, a great advantage of
hAM homogenate is also its ability to adhere to bladder cancer
cells but not normal urothelial cells.
To test whether the hAM homogenate has such a profound
effect on bladder cancer cells also in the 3D in vitro models,
we prepared the T24 and RT4 spheroids. Our results show
that already after 24 h of incubation in hAM homogenate, the
architecture of the bladder cancer spheroids was distorted, and
the effect was even more pronounced after 72 h of incubation.
Namely, the hAM homogenate was not only adhered to the
T24 and RT4 cells on the surface of the spheroid but also
penetrated the spheroids. Therefore, the important novelty of
our study is that we demonstrate for the first time that hAM
homogenate can disrupt the 3D structure of urothelial tumor
spheroids. Future studies must assess whether in the in vivo
conditions the hAM homogenate might decrease hypoxia and
angiogenesis in tumors and could also contribute to a more
efficient drug delivery in the case of the intravesical application
of chemotherapeutics.
hAM Homogenate and Future
Perspectives of Bladder Cancer
Treatment
Human amniotic membrane homogenate displays many
characteristics that would be beneficial in the treatment
of bladder cancer. Its anti-proliferative, anti-adhesive and
cell detachment-inducing properties suggest that hAM
homogenate could be used as adjuvant intravesical therapy
after transurethral resection of NMIBC tumors similarly as
intravesical chemotherapy and immunotherapy with BCG
are used now. According to the European Organization for
Research and Treatment of Cancer (EORTC), patients with
high risk NMIBC, which have high probability of progression
to MIBC (Sylvester et al., 2006), would benefit from additional
intravesical agent besides BCG, as BCG therapy either fails or
is contraindicated in certain patients. Immediate intravesical
instillation of hAM after transurethral resection of bladder
tumor (TURBT) could prevent reimplantation of cancer cells
that are present in urine due to surgical procedure, while its
anti-proliferative and detachment-inducing actions could target
cancer cells in bordering regions between tumor and normal
mucosa as well as invisible small satellite tumor nests growing in
other parts of bladder mucosa.
Furthermore, we believe future studies should be
aimed at investigating the effect of hAM homogenate in
combination with cytotoxic anticancer drugs, e.g., cisplatin-
based chemotherapeutics that remain the gold standard for
the treatment of bladder cancer (Dumont et al., 2019). The
hAM homogenate could serve as a drug delivery tool for
chemotherapeutics since several studies demonstrated the ability
of hAM to uptake antibiotics, nanoparticles and other drugs
(Kim et al., 2001; Mencucci et al., 2006; Resch et al., 2010, 2011;
Li et al., 2012; Hu et al., 2015; Yelchuri et al., 2017; Francisco
et al., 2020; Ramuta et al., 2020b). Moreover, their results show
that the uptake of the drug was dose-dependent and occurred
rapidly, but the release of the drug from hAM was sustained and
lasted for up to several days (Mencucci et al., 2006; Resch et al.,
2011; Yelchuri et al., 2017; Sara et al., 2019).
Human amniotic membrane homogenate could also
contribute to the regeneration of normal urothelium since it
was demonstrated that hAM and hAM-derived preparations
promote epithelization and decrease scarring (Koizumi et al.,
2000; Insausti et al., 2010; Jin et al., 2015; Rahman et al., 2019;
Rana et al., 2020). Moreover, our research group showed that
hAM scaffolds enable the development of tissue-engineered
urothelium with molecular and ultrastructural properties
comparable to that of the native urothelium (Jerman et al.,
2014) and that hAM scaffolds enriched with urinary bladder
fibroblasts promote the re-epithelization of urothelial injury
(Jerman et al., 2020). Additionally, recently we showed that
hAM homogenate possesses antimicrobial activity against
most common uropathogenic bacteria and multidrug-resistant
bacteria associated with urinary tract infections (Šket et al.,
2019; Ramuta et al., 2020b, 2021) and as such could prevent
urinary tract infections, which are one of the most common
bacterial infections in humans and also one of the most common
healthcare-associated infections (Flores-Mireles et al., 2015;
Wang et al., 2019). Therefore, the use of hAM homogenate could
prevent additional complications that could arise during the
treatment of bladder cancer.
Anticancer Activity of hAM-Derived
Preparations: Which Derivative
Encompasses the Most of the Beneficial
Properties of hAM?
Several research groups investigated the anticancer activity of
hAM using hAM-derived cells (Jiao et al., 2012; Kang et al., 2012;
Magatti et al., 2012; Bu et al., 2017), conditioned medium
prepared using hAM-derived cells (Niknejad et al., 2014; Kim
et al., 2015) or intact hAM (Niknejad et al., 2014; Modaresifar
et al., 2017; Riedel et al., 2019) and hAM extracts (Mamede
et al., 2014, 2015, 2016). As already mentioned, hAM-derived
cells decrease proliferation of cancer cells of hematopoietic and
non-hematopoietic origin and ovarian cancer cell line (Magatti
et al., 2012; Bu et al., 2017). Moreover, hAMSC induce apoptosis
of C6 glioma cells in in vivo BALB/c-nu mice model (Jiao
et al., 2012). hAM-derived conditioned medium has been shown
to inhibit DNA synthesis, decrease viability and number of
hepatocarcinoma cells and interestingly, induce cell cycle arrest
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in G2/M phase (Riedel et al., 2019). Moreover, Niknejad et al.
(2014) demonstrated that hAEC-derived conditioned medium
decreases viability of cervical cancer and breast cancer cell
lines and induces apoptosis (Niknejad et al., 2014). hAM
extracts induce cell morphology alterations, modify oxidative
stress environment and cell cycle in hepatocarcinoma cells,
affect the metabolism of various cancer cell lines and in some
hepatocarcinoma cell lines also lead to cell death (Mamede
et al., 2014, 2015, 2016). On the other hand, Kim et al. (2015)
showed that hAMSC-derived conditioned medium increased
proliferation and migration of breast cancer cells, MCF-7 and
MDA-MB-231 (Kim et al., 2015). Our previous study showed
that the hAEC and hAMSC in co-culture with T24 cancer cells
diminish the proliferation of cancer cells, while the hAM-derived
scaffolds altered the growth dynamic of T24 cells, reduced their
proliferation, decreased expression of epithelial-mesenchymal
transition markers N-cadherin, Snail and Slug. Moreover, despite
their muscle-invasive potential, the T24 cells did not disrupt the
basal lamina of hAM scaffolds even after 3 weeks in culture
(Ramuta et al., 2020a).
These studies show that hAM and hAM-derived preparations
are in various ways detrimental to cancer cells. Interestingly,
some of the studies show conflicting effects of hAM-derived
preparations in cancer cells of different origin, indicating that
the mechanism of action might be hAM-derived preparation-
specific and cell type-specific. Moreover, studies performed by
other research groups included the use of hAM-derived cells and
their conditioned medium or extract, but we have shown that
the hAM’s ECM is a monumental part of hAM and plays an
important role in its anticancer activity (Ramuta et al., 2020a).
However, when considering a potential clinical application, the
hAM scaffolds might be difficult to handle, especially when
considering the application in treatment of urological or breast
cancers. Hence, the need for another hAM-derived preparation
that would combine hAM-derived cells together with ECM arose.
In this study, we therefore prepared hAM homogenate for
investigating the anticancer properties of hAM and for the first
time we documented its effect on the morphology, attachment,
proliferation, cell cycle and ultrastructure of various cancer cells.
We obtained promising results that reveal the capability of
hAM homogenate to target several hallmarks of cancer cells.
However, it is of the utmost importance that future studies
identify the molecules in the hAM homogenate that induce
the detrimental effects in cancer cells and then determine their
mechanism of action.
CONCLUSION
This study demonstrates the multi-targeted anticancer activity
of hAM homogenate on several cancer cell lines and reveals
its potential to be used in bladder cancer treatment. We
hypothesize that if combined with cytotoxic anticancer drugs and
applied intravesically, the hAM homogenate could contribute
to treatment by (1) promoting detachment of bladder cancer
cells and preventing their re-attachment to the urothelium, (2)
decreasing proliferation of bladder cancer cells, (3) improving
targeting of bladder cancer cells without having a toxic effect
on normal urothelial cells and (4) improving drug delivery of
cytotoxic agents by disrupting the structure of bladder tumors.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will
be made available on request to corresponding author, without
undue reservation.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by the National Medical Ethics Committee of the
Republic of Slovenia and all participants provided their written
informed consent to participate in this study. The use of animal
tissues was reviewed and approved by Veterinary Administration
of the Slovenian Ministry of Agriculture and Forestry in
compliance with the Animal Health Protection Act and the
Instructions for Granting Permits for Animal Experimentation
for Scientific Purposes.
AUTHOR CONTRIBUTIONS
AJ, TŽR, and MEK designed the study. AJ, TŽR, LT, ŽS, and MEK
performed the experiments. AJ, TŽR, LT, and MEK analyzed and
interpreted the results. AJ and TŽR wrote the first draft of the
manuscript. All authors were involved in critically revising the
manuscript for important intellectual content, had full access to
the data, and approved the final manuscript.
FUNDING
The authors acknowledge the financial support from the
Slovenian Research Agency (Young-researcher funding, project
J7-2594, and research core funding No. P3-0108) and MRIC UL
IP-0510 Infrastructure program.
ACKNOWLEDGMENTS
The authors are thankful to Sanja Čabraja, Sabina Železnik,
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